Clinical Trial: Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study(STAR-01)

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07501169) titled 'Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study(STAR-01)' on March 24.

Brief Summary: This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC). The study is expected to enroll up to 33 eligible patients.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Intervention: DRUG: Sacituzum...